Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.8850 (-0.73%) ($10.8850 - $10.8850) on Fri. Nov. 18, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.07% (three month average) | RSI | 66 | Latest Price | $10.8850(-0.73%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.6% a day on average for past five trading days. | Weekly Trend | FOLD advances 5.1% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWO(45%) IWC(44%) IWM(44%) IWN(43%) | Factors Impacting FOLD price | FOLD will decline at least -1.535% in a week (0% probabilities). VIXM(-13%) VXX(-12%) XLU(-6%) UUP(-5%) TLT(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.535% (StdDev 3.07%) | Hourly BBV | -1.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $11.2(-2.81%) | 10 Day Moving Average | $11.02(-1.23%) | 20 Day Moving Average | $10.7(1.73%) | To recent high | -14.8% | To recent low | 8.9% | Market Cap | $2.811b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |